92 reports of this reaction
1.9% of all SUCCINYLCHOLINE CHLORIDE reports
#13 most reported adverse reaction
HYPERTHERMIA MALIGNANT is the #13 most commonly reported adverse reaction for SUCCINYLCHOLINE CHLORIDE, manufactured by Hospira, Inc.. There are 92 FDA adverse event reports linking SUCCINYLCHOLINE CHLORIDE to HYPERTHERMIA MALIGNANT. This represents approximately 1.9% of all 4,806 adverse event reports for this drug.
Patients taking SUCCINYLCHOLINE CHLORIDE who experience hyperthermia malignant should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERTHERMIA MALIGNANT is a less commonly reported adverse event for SUCCINYLCHOLINE CHLORIDE, but still significant enough to appear in the safety profile.
In addition to hyperthermia malignant, the following adverse reactions have been reported for SUCCINYLCHOLINE CHLORIDE:
The following drugs have also been linked to hyperthermia malignant in FDA adverse event reports:
HYPERTHERMIA MALIGNANT has been reported as an adverse event in 92 FDA reports for SUCCINYLCHOLINE CHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERTHERMIA MALIGNANT accounts for approximately 1.9% of all adverse event reports for SUCCINYLCHOLINE CHLORIDE, making it a notable side effect.
If you experience hyperthermia malignant while taking SUCCINYLCHOLINE CHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.